PathTracer: High-sensitivity detection of differential pathway activity in tumours

Ståle Nygård[1,2,*]**, Ole Christian Lingjærde**[1,3,4,*]**, Carlos Caldas**[5]**, Eivind Hovig**[1,6]**,**
Anne-Lise Børresen-Dale[3]**, ˚ Aslaug Helland**[3,7,8]**, and Vilde D. Haakensen**[3,7,†]

[1]Centre for Bioinformatics, Department of Informatics, University of Oslo, Oslo, Norway
[2]Bioinformatics core facility, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
[3]Department of Cancer Genetics, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
[4]KG Jebsen Centre for B-cell malignancies, Institute for Clinical Medicine, University of Oslo, Norway
[5]Cancer Research UK, Cambridge Research Institute, Li Ka Shing Centre, University of Cambridge, Cambridge, UK
[6]Department of Tumor Biology, Institute for Cancer Research, Oslo University Hospital, Oslo, Norway
[7]Department of Oncology, Oslo University Hospital, Oslo, Norway
[8]Institute of Clinical Medicine, University of Oslo, Oslo, Norway
[*]These authors contributed equally to this study
[†]Corresponding author vilde.haakensen@gmail.com

Histogram of PDS vs PTS correlation

Histogram of correlation between pathifier deregulation scores (PDS) and PathTracer scores (PTS) based on the metabric breast cancer dataset.